Ascendis Pharma A (ASND) Change in Receivables (2014 - 2026)
Ascendis Pharma A (ASND) reported Change in Receivables of -$42.6 million for Q1 2026, down 141.3% on a YoY basis from $103.1 million in Q1 2025, and down 140.01% sequentially from $106.5 million in Q4 2025.
Ascendis Pharma A (ASND) Change in Receivables (2014 - 2026) Analysis & Trends
Ascendis Pharma A (ASND) has 13 years of Change in Receivables data on file, last reported at -$42.6 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables fell 141.3% year-over-year to -$42.6 million; the trailing twelve-month figure through Mar 2026 stood at -$19.6 million (down 81.21% YoY), and the FY2025 full-year result was $135.7 million, up 205.72% from the prior year.
- Change in Receivables fell to -$42.6 million in Q1 2026, from $106.5 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $106.5 million in Q4 2025 to a low of -$133.4 million in Q4 2024.
- A 5-year average of -$5.3 million and a median of -$9.2 million in 2023 frame the typical range for Change in Receivables.
- Across the five-year window, Change in Receivables slumped 3786.48% in 2023 and jumped 941.05% in 2025, its largest moves.
- Tracing ASND's Change in Receivables over 5 years: stood at -$5.6 million in 2022, then slumped by 64.71% to -$9.2 million in 2023, then slumped by 1354.25% to -$133.4 million in 2024, then surged by 179.82% to $106.5 million in 2025, then tumbled by 140.01% to -$42.6 million in 2026.
- Business Quant data shows ASND's Change in Receivables at -$42.6 million in Q1 2026, $106.5 million in Q4 2025, and -$29.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ascendis Pharma A | 15.31 Bn | 14.64 Bn | 268.20 Mn | -42.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.59 Mn |
| Mar 31, 2026 | -42.59 Mn |
| Dec 31, 2025 | 106.45 Mn |
| Dec 31, 2025 | 106.45 Mn |
| Sep 30, 2025 | -29.12 Mn |
| Sep 30, 2025 | -29.12 Mn |
| Jun 30, 2025 | -54.32 Mn |
| Jun 30, 2025 | -54.32 Mn |
| Mar 31, 2025 | 103.12 Mn |
| Mar 31, 2025 | 103.12 Mn |
| Dec 31, 2024 | -133.36 Mn |
| Dec 31, 2024 | -133.36 Mn |
| Sep 30, 2024 | 31.78 Mn |
| Sep 30, 2024 | 31.78 Mn |
| Jun 30, 2024 | -12.34 Mn |
| Jun 30, 2024 | -12.34 Mn |
| Mar 31, 2024 | -12.26 Mn |
| Mar 31, 2024 | -12.26 Mn |
| Dec 31, 2023 | -9.17 Mn |
| Dec 31, 2023 | -9.17 Mn |